The firm believes the “real culprit” for Merck shares remaining under pressure is Keytruda’s 2028 patent expiration. Despite the company building out its pipeline, past precedence shows the ...

The safety profile of the combination therapy remains consistent, with no new adverse effects observed. Padcev plus Keytruda was found to maintain benefit over chemotherapy in untreated locally ...

Study shows that Libtayo plus chemotherapy has lower cost and a larger effect on improving quality-adjusted life years than Keytruda plus chemotherapy as first-line treatment for patients with ...

Enfortumab vedotin (EV; Padcev) alone and in combination with pembrolizumab (Keytruda) demonstrated promising clinical activity in upper tract urothelial carcinoma (UTUC) lesions, according to ...

The combination of Padcev and Keytruda showed promising clinical activity in UTUC patients, with a 25% ORR in primary lesions and 35% in target lesions. The study included 22 patients with intact ...

'ZDNET Recommends': What exactly does it mean? ZDNET's recommendations are based on many hours of testing, research, and comparison shopping. We gather data from the best available sources ...

The Pi Network coin was one of the first projects to get involved with the mobile crypto mining craze. Now, many investors are looking for a price prediction to see whether the token is worth mining.

There isn't enough evidence to support the use of Merck & Co/MSD's Keytruda in combination with chemotherapy as a first-line treatment for advanced triple negative breast cancer, according to the ...

This is a port of Arduino to the RP2040 (Raspberry Pi Pico processor) and RP2350 (Raspberry Pi Pico 2 processor). It uses the bare Raspberry Pi Pico SDK and a custom GCC 14.2/Newlib 4.3 toolchain and ...

Investors have taken to punishing pharma companies that appear unable to gauge demand for their top products.

Merck & Co.'s heavy reliance on its cancer drug Keytruda, which accounts for nearly half of the company's revenue, is raising investor concerns as the drug's patent expiration approaches in 2028 ...

In particular, Keytruda for cancer represents a key blockbuster with multi-billion-dollar potential: It holds a first-mover advantage in one of the largest cancer indications of non-small cell ...